查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1935709

Macitentan錠劑市場按患者類型、適應症、治療類型、劑量強度、品牌類型、最終用戶和分銷管道分類，全球預測，2026-2032年

Macitentan Tablets Market by Patient Type, Indication, Therapy Type, Dosage Strength, Brand Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Macitentan錠劑市場價值將達到 12 億美元，到 2026 年將成長至 12.8 億美元，到 2032 年將達到 18.8 億美元，複合年成長率為 6.57%。

主要市場統計數據
基準年 2025 12億美元
預計年份：2026年 12.8億美元
預測年份：2032年 18.8億美元
複合年成長率 (%) 6.57%

權威地介紹了現代Macitentan片劑環境的臨床概況、相關人員影響和實際考量

Macitentan已成為治療肺動脈高壓的核心治療選擇之一，其獨特的內皮素受體調節藥理特性使其脫穎而出。本執行摘要闡述了影響Macitentan錠劑市場格局的臨床、商業性和營運因素，重點分析了治療模式、監管趨勢和供應鏈因素如何共同影響藥物的可及性和應用。

近期臨床創新、監管演變和分銷現代化如何重塑Macitentan療法的交付方式和商業性定位？

在臨床創新、監管調整以及優先考慮門診和居家醫療的新型給藥模式的共同推動下，Macitentan片劑市場正經歷著變革性的變化。聯合治療的進步和對個人化治療日益重視正在改變臨床醫生的決策流程，促使他們在某些患者群體中更早啟動雙重或多重用藥策略。這些臨床轉變與肺血管疾病亞型診斷準確性的提高相輔相成，從而改變了治療性介入的時機和強度。

評估美國關稅調整對供應鏈、採購和定價造成的累積壓力及其對Macitentan取得的影響

計劃於2025年實施的新關稅措施和貿易政策調整將對Macitentan片劑的供應鏈、採購經濟效益以及整個治療生態系統的定價產生重大影響。藥品原料、製劑和包裝材料的關稅調整將增加製造商和下游經銷商的到岸成本，迫使他們重新評估其籌資策略、製造地和庫存管理實踐。

全面的細分分析揭示了患者群體、臨床適應症、治療方法、劑型、品牌趨勢和分銷管道如何影響Macitentan的使用。

基於患者類型、適應症、治療方法類型、劑量強度、品牌地位、最終用戶和分銷管道的詳細細分分析，揭示了Macitentan坦片劑需求和使用情況的細微促進因素。按患者類型分類的市場研究涵蓋成人和兒童人群，檢驗了每種人群獨特的臨床監測要求和給藥注意事項，這些因素會影響製劑的可接受性和依從性支持需求。按適應症分類的分析檢視了結締組織疾病相關性肺動脈高壓、特發性肺動脈高壓和分流相關性肺動脈高壓的市場。每種適應症的進展模式、合併症負擔和伴隨用藥情況各不相同，這些因素都會影響臨床決策。

區域醫療保健系統、監管差異和分銷能力將如何決定Macitentan片劑市場的准入管道並影響其策略優先順序？

區域趨勢將對Macitentan錠劑的可近性、監管方式和分銷網路發展產生重大影響。美洲各地的醫療保健系統各不相同，從高度整合的私人保險模式到強調成本控制的公共項目，這些差異會影響合約策略、報銷管道和患者負擔能力策略。主要都市區專科肺科中心和強大的臨床網路的普及支持集中實施，而遍遠地區的用藥仍然依賴遠端醫療和專科藥房推廣計畫。

策略性企業行動和夥伴關係模式將決定Macitentan錠產品組合的商業性永續性、差異化和市場准入結果。

Macitentan錠劑生產商之間的競爭，正日益體現在生命週期策略、夥伴關係模式和營運規模上，而非單純的產品市場佔有率。創新驅動型公司正透過強化臨床差異化、拓展適應症以及完善病患支援體系來捍衛其高階市場地位。具體策略包括進行有針對性的研究者主導試驗、提供可操作的真實世界證據項目，以及與專科藥房合作，以簡化患者治療的啟動和監測流程。

為確保Macitentan業務的持續成功，需採取綜合方法，包括臨床證據產生、供應鏈韌性以及有針對性的市場進入策略。

希望加強Macitentan業務的產業領導者應採取整合臨床差異化、供應鏈韌性和市場進入洞察的策略。首先，他們應投資於真實世界證據項目，記錄不同適應症和患者類型的治療結果，從而為支付者和臨床醫生提供更強力的價值提案。這些證據舉措應著重解決成人和兒童族群的依從性、長期安全性和療效比較問題，以降低支付方的不確定性並支持差異化合約。

採用透明的多源資訊來源調查方法，結合專家訪談和二手臨床及行業數據，以檢驗市場和臨床洞察。

本執行摘要的研究整合了多來源證據、系統性的專家參與和反覆檢驗，以確保其準確性和實用性。主要研究內容包括對肺血管疾病專科臨床醫生、負責配發先進療法的專科藥劑師、醫院採購負責人以及監管事務專家進行深度訪談，這些專家提供了有關核准和報銷機制的背景資訊。這些定性研究結果與來自臨床試驗註冊庫、同行評審文獻、監管申報文件和分銷數據的二手資訊進行三角驗證，從而繪製出供應鏈和分銷模式圖。

在Macitentan治療中，臨床、運作和可近性等關鍵要素的整合對於持續創造價值和患者治療的連續性至關重要。

總之，Macitentan坦錠在肺動脈高壓的治療中佔據戰略地位，其特點是臨床實踐不斷發展、分銷管道現代化以及對價值論證的日益重視。患者細分、適應症特異性治療管道以及不斷變化的區域准入趨勢的交匯，為產品生命週期中的各相關人員帶來了機會和挑戰。應對這些趨勢需要協調投資於實證醫學、供應鏈柔軟性以及與支付方、醫療服務提供者和患者需求相符的有針對性的市場進入措施。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 依患者類型分類的Macitentan錠市場

  • 成人
  • 兒童

第9章Macitentan錠劑市場（依適應症分類）

  • 結締組織疾病相關性肺動脈高血壓
  • 特發性肺動脈高血壓
  • 分流相關性肺動脈高血壓

第10章Macitentan錠劑市場依治療類型分類

  • 聯合治療
  • 單藥治療

第11章Macitentan錠劑市場依劑量強度分類

  • 10mg
  • 5mg

第12章Macitentan坦錠劑市場（依品牌類型分類）

  • 品牌Macitentan
  • 非專利Macitentan替坦

第13章Macitentan坦錠劑市場：依最終用戶分類

  • 門診治療中心
  • 醫院
  • 專科診所

第14章Macitentan坦錠劑市場依通路分類

  • 離線頻道
    • 醫院藥房
    • 零售藥房
  • 網路藥房

第15章 各地區Macitentan錠劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章Macitentan坦錠劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國Macitentan錠劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 美國Macitentan錠劑市場

第19章 中國Macitentan錠劑市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actelion Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila
Product Code: MRR-9A6A6F2974CA

The Macitentan Tablets Market was valued at USD 1.20 billion in 2025 and is projected to grow to USD 1.28 billion in 2026, with a CAGR of 6.57%, reaching USD 1.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.20 billion
Estimated Year [2026] USD 1.28 billion
Forecast Year [2032] USD 1.88 billion
CAGR (%) 6.57%

An authoritative introduction to the clinical profile, stakeholder implications, and practical considerations shaping the contemporary macitentan tablet environment

Macitentan has emerged as a central therapeutic option in the management of pulmonary arterial hypertension, bringing a distinct pharmacological profile to bear on endothelin receptor modulation. This executive summary introduces the clinical, commercial, and operational considerations that shape the macitentan tablet landscape, highlighting how treatment paradigms, regulatory dynamics, and supply chain forces converge to influence access and adoption.

The initial portion of this analysis situates macitentan within the broader therapeutic class by synthesizing clinical efficacy and safety observations alongside real-world usage patterns. It distinguishes patient cohorts by age and clinical presentation, and connects these patient-level dynamics to prescribing behavior among specialty clinicians. Moreover, it frames the evolving payer, hospital, and pharmacy responses that mediate uptake and adherence.

In framing the report, emphasis is placed on cross-functional implications for manufacturers, distributors, and providers. By examining clinical evidence, product differentiation, and distribution mechanics in tandem, this introduction provides readers with a cohesive lens through which to interpret subsequent sections. The result is a pragmatic, evidence-based foundation that prepares stakeholders to evaluate strategy options with clarity and confidence.

How recent clinical innovations, regulatory evolution, and distribution modernisation are reshaping macitentan therapy delivery and commercial positioning

The macitentan landscape is undergoing transformative shifts driven by converging clinical innovations, regulatory recalibrations, and changing delivery models that prioritize outpatient and home-based care. Advances in combination regimens and an increasing emphasis on personalized therapy have altered clinician decision pathways, prompting earlier initiation of dual or multi-drug strategies in select patient populations. These clinical shifts are complemented by enhancements in diagnostic acuity that identify pulmonary vascular disease subtypes sooner, thereby changing the timing and intensity of treatment interventions.

Concurrently, regulatory pathways in major jurisdictions are evolving to accommodate lifecycle management through label expansions and novel evidence packages, which in turn shape commercial strategies for differentiated formulations and dosing options. On the distribution side, digital pharmacy channels and integrated specialty pharmacy services are gaining prominence, requiring manufacturers to rethink patient support, adherence programs, and fulfillment logistics. Supply chain optimization and risk mitigation have moved to the foreground as manufacturers balance resilience with cost pressures, adopting dual-sourcing for active pharmaceutical ingredients and closer supplier oversight.

Collectively, these transformative forces create new opportunities for targeted clinical trials, value-based contracting, and differentiated patient engagement models. For stakeholders, the imperative is to align R&D, market access, and commercial operations so that clinical innovation translates into sustainable patient access and long-term portfolio resilience.

Assessing the cumulative supply chain, procurement, and pricing pressures stemming from United States tariff policy adjustments and their implications for macitentan access

The introduction of new tariff measures and trade policy shifts projected for the United States in 2025 has important implications for the macitentan tablet supply chain, procurement economics, and pricing dynamics across the therapeutic ecosystem. Tariff adjustments on pharmaceutical inputs, finished dosage forms, or packaging components can increase landed costs for manufacturers and downstream distributors, creating pressure to re-evaluate sourcing strategies, manufacturing footprints, and inventory management practices.

In response to potential tariff-driven cost increases, manufacturers may accelerate domestic manufacturing investments, transfer production lines to tariff-safe jurisdictions, or renegotiate supplier contracts to preserve margins while maintaining continuity of supply. These strategic moves can introduce lead time variability and transitional capacity constraints that require close coordination with providers and specialty pharmacies. Payers and hospital procurement teams may also adjust formulary decisions in favor of therapeutically equivalent options that demonstrate lower acquisition volatility, thereby influencing prescribing patterns.

Additionally, tariff-related uncertainty can prompt more aggressive use of long-term contracts, hedging strategies, and collaborative procurement across integrated delivery networks. For innovators, the need to justify premium pricing intensifies, pushing manufacturers to reinforce evidence of differentiated clinical value and to pursue risk-sharing agreements where appropriate. Ultimately, the cumulative impact of tariff shifts is to magnify the importance of supply chain transparency, agile manufacturing, and value demonstration in preserving patient access to macitentan therapy.

Comprehensive segmentation analysis revealing how patient cohorts, clinical indications, therapies, dosage forms, brand dynamics, and distribution channels shape macitentan utilization

A granular segmentation lens reveals the nuanced drivers of demand and utilization for macitentan tablets when analyses are anchored to patient type, indication, therapy type, dosage strength, brand status, end user, and distribution channel. Based on Patient Type, the market is studied across Adult and Pediatric cohorts, each presenting distinct clinical monitoring requirements and dosing considerations that affect formulation acceptance and adherence support needs. Based on Indication, the market is studied across CTD Associated PAH, Idiopathic PAH, and Shunt Associated PAH, with each indication exhibiting different progression patterns, comorbidity burdens, and concomitant medication profiles that influence clinical decision-making.

When viewed through Therapy Type, the market is studied across Combination Therapy and Monotherapy, highlighting the growing role of concurrent agents in achieving optimal hemodynamic outcomes and the operational implications for dosing complexity and adverse event management. Based on Dosage Strength, the market is studied across 10 Mg and 5 Mg presentations, which shape prescribing flexibility and inventory segmentation across pharmacies and hospitals. Based on Brand Type, the market is studied across Branded Macitentan and Generic Macitentan, with brand equity, patent status, and bioequivalence considerations driving differentiated access strategies.

Finally, Based on End User, the market is studied across Ambulatory Care Centers, Hospitals, and Specialty Clinics, while Based on Distribution Channel, the market is studied across Offline Channels and Online Pharmacy, with Offline Channels further studied across Hospital Pharmacy and Retail Pharmacy. This multi-dimensional segmentation framework clarifies where clinical demand intersects with commercial pathways and where targeted interventions-such as adherence programs, clinician education, and formulary strategies-can most effectively influence outcomes.

How regional healthcare architectures, regulatory heterogeneity, and distribution capabilities determine access pathways and prioritise tailored macitentan market strategies

Regional dynamics exert material influence on macitentan tablet accessibility, regulatory approaches, and the configuration of distribution networks. In the Americas, healthcare systems vary from highly integrated private-payer models to public programs that emphasize cost containment, which affects contracting strategies, reimbursement pathways, and patient affordability measures. The prevalence of specialized pulmonary centers and robust clinical networks in major urban centers supports concentrated adoption, whereas rural access continues to rely on telemedicine and specialty pharmacy outreach programs.

In Europe, Middle East & Africa, heterogeneity in regulatory standards and reimbursement frameworks creates a patchwork of market entry considerations. Countries with centralized health technology assessment systems require compelling comparative effectiveness data and health economic dossiers, while other jurisdictions prioritize expedited access for orphan or high-need therapies. Distribution infrastructure differences and variable cold-chain capabilities influence inventory strategies, particularly for multi-dose regimens and hospital-centric dispensation.

In Asia-Pacific, the interplay of emerging middle-income markets and established high-income systems drives a dual focus on rapid access and cost containment. Local manufacturing initiatives and regional trade agreements shape supply pathways, while differential rates of specialty care development determine the pace of adoption. Across all regions, the common themes are the need for evidence of real-world effectiveness, tailored patient support solutions, and partnerships that bridge clinical, payer, and distribution stakeholder interests to expand appropriate access.

Strategic company behaviours and partnership models that determine commercial resilience, differentiation, and access outcomes for macitentan tablet portfolios

Competitive behavior among companies involved with macitentan tablets is increasingly defined by life cycle strategies, partnership models, and operational scale rather than simple product presence. Innovator-oriented firms focus on reinforcing clinical differentiation, pursuing label expansions, and strengthening patient support ecosystems to defend premium positioning. Their tactics include targeted investigator-sponsored studies, pragmatic real-world evidence programs, and collaborations with specialty pharmacies to streamline patient initiation and monitoring.

At the same time, generic entrants and specialty manufacturers concentrate on cost-efficient production, regulatory filings for bioequivalence, and rapid market entry tactics that leverage established distribution relationships. Contract manufacturing organizations and advanced formulation developers play a pivotal role by enabling capacity flexibility and by offering services that accelerate time-to-shelf for secondary suppliers. Across the competitive spectrum, supply chain reliability and quality certification remain critical differentiators that influence purchasing decisions by hospitals and pharmacies.

Partnerships between commercial stakeholders and clinical networks are also emerging as a decisive factor, enabling coordinated patient education, adherence tracking, and value articulation to payers. Companies that combine robust clinical evidence with operational excellence in distribution and patient services are positioned to capture the highest utility from the macitentan therapeutic class, while those that fail to invest in integrated post-launch support risk rapid erosion of uptake in competitive tendering and formulary evaluations.

Actionable strategic imperatives to combine clinical evidence generation, supply chain resilience, and targeted market access tactics for durable macitentan success

Industry leaders seeking to strengthen their macitentan franchises should pursue integrated strategies that combine clinical differentiation, supply chain resilience, and market access acumen. First, invest in real-world evidence programs that document outcomes across diverse indications and patient types, thereby enabling stronger value propositions to payers and clinicians. These evidence initiatives should be designed to address adherence, long-term safety, and comparative effectiveness in both adult and pediatric cohorts to reduce payer uncertainty and to support differentiated contracting.

Second, diversify manufacturing and sourcing strategies to mitigate tariff and geopolitical risk, including dual-sourcing of active pharmaceutical ingredients, nearshoring options, and strategic inventory buffers. By proactively addressing potential supply disruptions, companies can preserve continuity of care for patients dependent on chronic therapy. Third, tailor commercial deployment by aligning dosage strength availability, branded versus generic positioning, and pharmacy distribution models to the specific needs of ambulatory centers, hospitals, and specialty clinics. This nuanced approach improves patient initiation and reduces friction in the dispensing process.

Finally, enhance payer and provider engagement through outcome-aligned contracting, bundled care pilots, and targeted patient support programs that reduce administrative burden and optimize adherence. By operationalizing these recommendations, manufacturers and stakeholders can convert clinical advances into sustained patient access and commercial viability while navigating the complex policy and market shifts that define the current environment.

A transparent, multi-source research methodology combining primary expert interviews and secondary clinical and trade data to validate market and clinical insights

The research underpinning this executive summary integrates multi-source evidence, structured expert engagement, and iterative validation to ensure accuracy and practical relevance. Primary research components included in-depth interviews with clinicians specializing in pulmonary vascular disease, specialty pharmacists responsible for dispensing advanced therapies, hospital procurement officers, and regulatory affairs professionals who provided context on approval and reimbursement mechanisms. These qualitative insights were triangulated with secondary sources obtained from clinical trial registries, published peer-reviewed literature, regulatory submissions, and trade data to map supply chain and distribution patterns.

Analytical rigor was reinforced through a structured synthesis process that converted clinical findings into operational implications; for example, translating dosing variability into inventory segmentation needs across different end users. Data quality checks involved cross-verification of clinical outcomes with published study endpoints and confirmation of regulatory timelines against public filings. Where uncertainties remained, follow-up interviews and sensitivity reviews were conducted with domain experts to reconcile conflicting inputs and to highlight areas requiring further primary investigation.

Finally, the methodology emphasizes transparency and reproducibility by documenting data sources, interview protocols, and analytical assumptions. This approach allows stakeholders to assess the validity of insights, request targeted replications, and commission custom analyses that extend the core findings into specific geographies, patient subgroups, or commercial scenarios.

Conclusive synthesis of clinical, operational, and access imperatives that define durable value creation and patient continuity for macitentan therapies

In conclusion, macitentan tablets occupy a strategic position within pulmonary arterial hypertension management, characterized by evolving clinical practice, distribution modernisation, and increased emphasis on value demonstration. The intersection of patient segmentation, indication-specific treatment pathways, and shifting regional access dynamics creates both opportunities and risks for stakeholders across the product lifecycle. Addressing these dynamics requires coordinated investments in evidence generation, supply chain flexibility, and targeted market access initiatives that align with the needs of payers, providers, and patients.

Manufacturers and partners that anticipate tariff and trade disruptions, invest in local and regional manufacturing resilience, and commit to robust real-world data collection will be better positioned to sustain access while defending commercial value. At the same time, a focused approach to segmentation-attending to differences by patient type, indication, therapy modality, dosage strength, brand status, and distribution channel-will enable more efficient allocation of resources and more impactful interventions to improve adherence and outcomes.

Ultimately, the path to long-term success in the macitentan space rests on the ability to convert clinical promise into demonstrable value for healthcare systems, to ensure supply continuity for patients, and to craft commercially viable models that support innovation while maintaining affordability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Macitentan Tablets Market, by Patient Type

  • 8.1. Adult
  • 8.2. Pediatric

9. Macitentan Tablets Market, by Indication

  • 9.1. CTD Associated PAH
  • 9.2. Idiopathic PAH
  • 9.3. Shunt Associated PAH

10. Macitentan Tablets Market, by Therapy Type

  • 10.1. Combination Therapy
  • 10.2. Monotherapy

11. Macitentan Tablets Market, by Dosage Strength

  • 11.1. 10 Mg
  • 11.2. 5 Mg

12. Macitentan Tablets Market, by Brand Type

  • 12.1. Branded Macitentan
  • 12.2. Generic Macitentan

13. Macitentan Tablets Market, by End User

  • 13.1. Ambulatory Care Centers
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Macitentan Tablets Market, by Distribution Channel

  • 14.1. Offline Channels
    • 14.1.1. Hospital Pharmacy
    • 14.1.2. Retail Pharmacy
  • 14.2. Online Pharmacy

15. Macitentan Tablets Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Macitentan Tablets Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Macitentan Tablets Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Macitentan Tablets Market

19. China Macitentan Tablets Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Actelion Pharmaceuticals Ltd.
  • 20.6. Alembic Pharmaceuticals Limited
  • 20.7. Aurobindo Pharma Limited
  • 20.8. Cipla Limited
  • 20.9. Dr. Reddy's Laboratories Ltd.
  • 20.10. Glenmark Pharmaceuticals Ltd.
  • 20.11. Hetero Labs Limited
  • 20.12. Johnson & Johnson
  • 20.13. Lupin Limited
  • 20.14. Mylan N.V.
  • 20.15. Sun Pharmaceutical Industries Ltd.
  • 20.16. Torrent Pharmaceuticals Ltd.
  • 20.17. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MACITENTAN TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MACITENTAN TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY CTD ASSOCIATED PAH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY CTD ASSOCIATED PAH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY CTD ASSOCIATED PAH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY IDIOPATHIC PAH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY IDIOPATHIC PAH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY IDIOPATHIC PAH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SHUNT ASSOCIATED PAH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SHUNT ASSOCIATED PAH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SHUNT ASSOCIATED PAH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 10 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 10 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 10 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 5 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 5 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY 5 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRANDED MACITENTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRANDED MACITENTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY BRANDED MACITENTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GENERIC MACITENTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GENERIC MACITENTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GENERIC MACITENTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 152. GCC MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GCC MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 174. G7 MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 179. G7 MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. G7 MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. NATO MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 188. NATO MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. NATO MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL MACITENTAN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA MACITENTAN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA MACITENTAN TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA MACITENTAN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA MACITENTAN TABLETS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA MACITENTAN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA MACITENTAN TABLETS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA MACITENTAN TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA MACITENTAN TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA MACITENTAN TABLETS MARKET SIZE, BY OFFLINE CHANNELS, 2018-2032 (USD MILLION)